We advised the representatives of the underwriters on the offering

Davis Polk advised the representatives of the underwriters in connection with the $250 million public offering of common stock and pre-funded warrants to purchase shares of common stock of CytomX Therapeutics, Inc. The shares are listed on the Nasdaq Global Select Market under the symbol “CTMX.”

CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer.

The Davis Polk corporate team included partners Alan F. Denenberg and Beth LeBow and associates Savannah J. Dowling and Alexis Aguila Johnson. Partner David R. Bauer and associates Shreya R. Kundur and Nazli Ungan provided intellectual property advice. Counsel Yixuan Long and associate David J. Beer provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post